EUVIMEDEUVIMED entdecken
Crossref

Residual red blood cells in liquid plasma products: A quality assessment

Furkan Yigitbilek iD, Suchitra Pandey, Tho Pham iD, Mrigender Singh Virk

American Journal of Clinical Pathology · 2025

DOI: 10.1093/ajcp/aqaf036 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Clinical Pathology, 2025. Verfasst von Furkan Yigitbilek und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Stanford University School of Medicine, Stanford, CA, United States. Hauptthemen laut MEDLINE: Erythrocytes, Plasma, Blood Preservation. Die Arbeit nennt 11 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Liquid plasma (LP) is an increasingly utilized blood product due to its immediate availability for transfusion without requiring thawing. While concerns exist regarding the presence of intact residual red blood cells (RBCs) in plasma products that have never been frozen, limited data are available on their levels in LP. This study aimed to evaluate residual RBC content in LP products to assess their safety for transfusion.

Methods

Liquid plasma units were prepared from whole-blood donations at the Stanford Blood Center. Seven group AB-positive, 1 group AB-negative, 10 group A-positive, and 2 group A-negative whole-blood units were collected in citrate phosphate dextrose anticoagulant, stored at 1 °C to 6 °C for 24 hours, centrifuged, and processed into LP. On day 2 of storage, 2-mL plasma samples were analyzed for RBC count, hemoglobin, and hematocrit.

Results

No residual RBCs were detected in any LP units, with all samples showing RBC counts below the limit of detection, hemoglobin levels of 0 g/dL, and hematocrit values of 0%. Given the uniform absence of RBC contamination, statistical analysis was not required.

Conclusions

The findings confirm that LP prepared under current blood processing standards contains no detectable residual RBCs, supporting its safety for transfusion with ABO-compatible products without the need for consideration of RhD compatibility.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ErythrocytesPlasmaBlood PreservationHumansErythrocyte CountHematocrit

Stichwörter der Autor:innen

RhD compatibility requirementsliquid plasmatransfusion safety

Autor:innen und Institutionen

  • Department of Pathology, Stanford University School of Medicine, Stanford, CA, United States.

ORCID-Profile: Furkan Yigitbilek, Tho Pham

Zitieren

APA

Yigitbilek, F., Pandey, S., Pham, T., & Virk, M. S. (2025). Residual red blood cells in liquid plasma products: A quality assessment. American Journal of Clinical Pathology. https://doi.org/10.1093/ajcp/aqaf036

Vancouver

Yigitbilek F, Pandey S, Pham T, Virk MS. Residual red blood cells in liquid plasma products: A quality assessment. American Journal of Clinical Pathology. 2025. doi:10.1093/ajcp/aqaf036

BibTeX
@article{Yigitbilek2025,
  author = {Yigitbilek, Furkan and Pandey, Suchitra and Pham, Tho and Virk, Mrigender Singh},
  title = {Residual red blood cells in liquid plasma products: A quality assessment},
  journal = {American Journal of Clinical Pathology},
  year = {2025},
  doi = {10.1093/ajcp/aqaf036}
}
Kostenlos starten →